AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34244787 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 34275872 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led HIVST
Number of subjects: 11150
Study 34275872 — intervention group
Group type: COMPARATOR
Intervention: Paid distribution (PD)
Number of subjects: 11150
Study 35334389 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0
Study 35334389 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 35011059 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g fish oil daily for 6 weeks
Number of subjects: 85
Study 35011059 — intervention group
Group type: COMPARATOR
Intervention: 6 g soybean oil daily for 6 weeks
Number of subjects: 85
Study 35011059 — intervention group
Group type: COMPARATOR
Intervention: 3 g of each (fish oil and soybean oil) daily for 6 weeks
Number of subjects: 85
Study 34187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative imaging with magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 13680
Study 34187817 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (no preoperative imaging)
Number of subjects: 13680
Study 34187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative imaging with MRCP
Number of subjects: 13680
Study 32024400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented DM cup fixation (n = 30)
Number of subjects: 60
Study 32024400 — intervention group
Group type: COMPARATOR
Intervention: Cementless DM cup fixation (n = 30)
Number of subjects: 60
Study 36113023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber, high-fruit and vegetable, low-fat dietary intervention
Number of subjects: 368
Study 36113023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 368
Study 36113023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial dietary fiber intake
Number of subjects: 368
Study 34530738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure management (< 120/80 mmHg)
Number of subjects: 173
Study 34530738 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure management (< 140/90 mmHg)
Number of subjects: 173
Study 34825264 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium lactis Probio-M8 (2 × 10^10 log CFU/day)
Number of subjects: 60
Study 34825264 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium lactis Probio-M8
Number of subjects: 60
Study 34825264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35593522 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin (PRF)
Number of subjects: 12
Study 35593522 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 12
Study 33720388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg sugammadex
Number of subjects: 102
Study 33720388 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg sugammadex
Number of subjects: 102
Study 32108888 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise program plus nurse consultations
Number of subjects: 140
Study 32108888 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief nurse consultation)
Number of subjects: 140
Study 35723242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 112
Study 35723242 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasal spray
Number of subjects: 112
Study 35723242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 112
Study 35723242 — intervention group
Group type: COMPARATOR
Intervention: Placebo control protocol
Number of subjects: 112
Study 33260523 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cooking intervention (hands-on lesson)
Number of subjects: 0
Study 33260523 — intervention group
Group type: COMPARATOR
Intervention: Demonstration cooking intervention (observing a chef)
Number of subjects: 0
Study 33260523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (active and demonstration)
Number of subjects: 0
Study 32941962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia
Number of subjects: 0
Study 32941962 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia
Number of subjects: 0
Study 33257487 — intervention group
Group type: EXPERIMENTAL
Intervention: Champion support in implementation of the Back Skills Training (BeST) programme
Number of subjects: 0
Study 33257487 — intervention group
Group type: COMPARATOR
Intervention: Standard training for physiotherapists without champion support
Number of subjects: 0
Study 36413792 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Ara-C plus pegylated recombinant arginase BCT-100
Number of subjects: 83
Study 36413792 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Ara-C (LDAC)
Number of subjects: 83
Study 33582621 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation therapy in addition to exercise (n = 18)
Number of subjects: 36
Study 33582621 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (Control group, n = 18)
Number of subjects: 36
Study 32398113 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40-80 mg twice daily) in addition to standard care
Number of subjects: 0
Study 32398113 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (i.e. anti-epileptic drugs or headache treatments)
Number of subjects: 0
Study 36075235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered after childbirth
Number of subjects: 33
Study 36075235 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered after childbirth
Number of subjects: 33
Study 33648495 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in seeking treatment for pelvic organ prolapse
Number of subjects: 123
Study 33648495 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with delay in treatment
Number of subjects: 123
Study 32811613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulsed ultrasound combined with alteplase intravenous thrombolysis
Number of subjects: 82
Study 32811613 — intervention group
Group type: COMPARATOR
Intervention: Alteplase intravenous thrombolytic treatment
Number of subjects: 82
Study 34855212 — intervention group
Group type: EXPERIMENTAL
Intervention: StressProffen intervention (n = 84)
Number of subjects: 172
Study 34855212 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n = 88)
Number of subjects: 172
Study 34101691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week immobilization
Number of subjects: 111
Study 34101691 — intervention group
Group type: COMPARATOR
Intervention: 3-week immobilization
Number of subjects: 111
Study 33032585 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 5% ointment
Number of subjects: 72
Study 33032585 — intervention group
Group type: COMPARATOR
Intervention: Vaseline ointment (placebo)
Number of subjects: 72
Study 35096422 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA)
Number of subjects: 23
Study 35096422 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA)
Number of subjects: 23
Study 32247219 — intervention group
Group type: COMPARATOR
Intervention: Cole formula
Number of subjects: 135
Study 32247219 — intervention group
Group type: EXPERIMENTAL
Intervention: Duracher formula
Number of subjects: 135
Study 32247219 — intervention group
Group type: COMPARATOR
Intervention: Khine formula
Number of subjects: 135
Study 34438110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + Dexamethasone (3 cc 2% lidocaine + 1 cc dexamethasone, 4 mg)
Number of subjects: 60
Study 34438110 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone (3 cc 2% lidocaine + 1 cc normal saline)
Number of subjects: 60
Study 32500131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine (5 mg/kg)
Number of subjects: 70
Study 32500131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32009778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) of gemigliptin (50 mg) and rosuvastatin (20 mg)
Number of subjects: 37
Study 32009778 — intervention group
Group type: COMPARATOR
Intervention: Loose combination of gemigliptin (50 mg) and rosuvastatin (20 mg)
Number of subjects: 37
Study 35658048 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional and speckle-tracking echocardiography
Number of subjects: 1441
Study 35658048 — intervention group
Group type: COMPARATOR
Intervention: Validation sample from the Copenhagen City Heart Study
Number of subjects: 1441
Study 34948486 — intervention group
Group type: EXPERIMENTAL
Intervention: Early occupational therapy intervention program
Number of subjects: 60
Study 34948486 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study 33791888 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 42
Study 33791888 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42
Study 33498049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU daily for 3 days before surgery)
Number of subjects: 111
Study 33498049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 32498098 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSE technique
Number of subjects: 244
Study 32498098 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique without ROSE
Number of subjects: 244
Study 35550031 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 60
Study 35550031 — intervention group
Group type: COMPARATOR
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 60
Study 33167040 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth tourism (BT) infants
Number of subjects: 1755
Study 33167040 — intervention group
Group type: COMPARATOR
Intervention: Non-BT control infants
Number of subjects: 1755
Study 32800386 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 μg) and vitamin-B12 (500 μg) supplementation
Number of subjects: 2919
Study 32800386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2919
Study 35331681 — intervention group
Group type: EXPERIMENTAL
Intervention: Telestration group
Number of subjects: 20
Study 35331681 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching group
Number of subjects: 20
Study 33252627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0
Study 33252627 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36121303 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB interval of 35 minutes
Number of subjects: 100
Study 36121303 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB interval of 40 minutes
Number of subjects: 100
Study 36121303 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB interval of 45 minutes
Number of subjects: 100
Study 36121303 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB interval of 50 minutes
Number of subjects: 100
Study 36121303 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB interval of 55 minutes
Number of subjects: 100
Study 36121303 — intervention group
Group type: EXPERIMENTAL
Intervention: DPE technique with ropivacaine 0.1% and sufentanil 0.5 μg/mL
Number of subjects: 100
Study 33440301 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic Memory and Reasoning Training (SMART) (n = 38)
Number of subjects: 81
Study 33440301 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Workshop (control) (n = 43)
Number of subjects: 81
Study 34184930 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded quantitative urine culture (EQUC)
Number of subjects: 225
Study 34184930 — intervention group
Group type: COMPARATOR
Intervention: Standard urine culture (SUC)
Number of subjects: 225
Study 32546834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic decision aid (DA)
Number of subjects: 2119
Study 32546834 — intervention group
Group type: COMPARATOR
Intervention: Standard brochure (SB)
Number of subjects: 2119
Study 34459055 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuVein arm
Number of subjects: 304
Study 34459055 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 304
Study 33990239 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT PE completers
Number of subjects: 35
Study 33990239 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT PE initiators
Number of subjects: 35
Study 33990239 — intervention group
Group type: COMPARATOR
Intervention: DBT only
Number of subjects: 35
Study 35159318 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day), n = 118
Number of subjects: 219
Study 35159318 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 101
Number of subjects: 219
Study 35159318 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation
Number of subjects: 219
Study 33745082 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of infertility services
Number of subjects: 12456
Study 33745082 — intervention group
Group type: COMPARATOR
Intervention: Not accessing infertility services
Number of subjects: 12456
Study 33745082 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization trends
Number of subjects: 12456
Study 33745082 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance status
Number of subjects: 12456
Study 33745082 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance status and utilization of infertility care
Number of subjects: 12456
Study 32917271 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily
Number of subjects: 0
Study 32917271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35081595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital low titer group O whole blood (LTOWB)
Number of subjects: 86
Study 35081595 — intervention group
Group type: COMPARATOR
Intervention: Standard prehospital air medical care (including red cell transfusion and crystalloids)
Number of subjects: 86
Study 35081595 — intervention group
Group type: COMPARATOR
Intervention: Prehospital low titer group O whole blood (LTOWB) and Standard care
Number of subjects: 86
Study 34145880 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg twice a day
Number of subjects: 50
Study 34145880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32570237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OIT (20 mL; n = 19)
Number of subjects: 33
Study 32570237 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose OIT (100 mL; n = 14)
Number of subjects: 33
Study 33103925 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session schema group therapy plus treatment as usual (TAU) (n = 28)
Number of subjects: 42
Study 33103925 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (n = 14)
Number of subjects: 42
Study 33704925 — intervention group
Group type: COMPARATOR
Intervention: Single-ascending-dose oral edaravone (30 to 300 mg)
Number of subjects: 140
Study 33704925 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose edaravone (120 mg/day for 5 or 8 days)
Number of subjects: 140
Study 33704925 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral edaravone
Number of subjects: 140
Study 33704925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral edaravone formulations
Number of subjects: 140
Study 33267545 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)2 apexification (group 1, n=6)
Number of subjects: 12
Study 33267545 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedure (REP) (group 2, n=6)
Number of subjects: 12
Study 33267545 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Ca(OH)2 apexification and REP)
Number of subjects: 12
Study 33267545 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)2 apexification
Number of subjects: 12
Study 33267545 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedure (REP)
Number of subjects: 12
Study 36046952 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral melatonin liquid
Number of subjects: 2
Study 36046952 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral melatonin liquid
Number of subjects: 2
Study 33657114 — intervention group
Group type: EXPERIMENTAL
Intervention: Early convalescent plasma (CP) therapy
Number of subjects: 58
Study 33657114 — intervention group
Group type: COMPARATOR
Intervention: Deferred convalescent plasma (CP) therapy
Number of subjects: 58
Study 32087837 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based relapse prevention program (e‐SMARPP)
Number of subjects: 48
Study 32087837 — intervention group
Group type: COMPARATOR
Intervention: web‐based self‐monitoring (control group)
Number of subjects: 48
Study 34907443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating alarm watch
Number of subjects: 243
Study 34907443 — intervention group
Group type: COMPARATOR
Intervention: Non-alarming watch (Control)
Number of subjects: 243
Study 33811684 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Video (MV) therapy
Number of subjects: 116
Study 33811684 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 35253117 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (placebo-controlled trial)
Number of subjects: 1889
Study 35253117 — intervention group
Group type: EXPERIMENTAL
Intervention: Final prediction model including IVH, PVL, gestational age, and gender
Number of subjects: 1889
Study 33200221 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa_circRNA_100876 inhibition
Number of subjects: 0
Study 33200221 — intervention group
Group type: EXPERIMENTAL
Intervention: differentially expressed circRNAs
Number of subjects: 0
Study 33200221 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa_circRNA_100876
Number of subjects: 0
Study 33345938 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 1116
Study 33345938 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1116
Study 33345938 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor and expectant management
Number of subjects: 1116
Study 35690008 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents with SM
Number of subjects: 28
Study 35690008 — intervention group
Group type: COMPARATOR
Intervention: Control group without SM
Number of subjects: 28
Study 34526088 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback and facilitated meetings
Number of subjects: 1900000
Study 34526088 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1900000
Study 32568327 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD diet containing 0.2% UA (UAL)
Number of subjects: 32
Study 32568327 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD diet containing 0.4% UA (UAH)
Number of subjects: 32
Study 32568327 — intervention group
Group type: COMPARATOR
Intervention: HCD diet
Number of subjects: 32
Study 32568327 — intervention group
Group type: COMPARATOR
Intervention: NCD
Number of subjects: 32
Study 34951444 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD-PAL intervention (eight 30-min videoconferencing sessions over 20 weeks with an interventionist + Fitbit + exercise prescription)
Number of subjects: 60
Study 34951444 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Fitbit + exercise prescription)
Number of subjects: 60
Study 35351445 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestrel 0.075 mg progestogen-only pill
Number of subjects: 52
Study 33758132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL nalbuphine with 10 mL 0.1% ropivacaine
Number of subjects: 180
Study 33758132 — intervention group
Group type: COMPARATOR
Intervention: 0.3 μg/mL sufentanil with 10 mL 0.1% ropivacaine
Number of subjects: 180
Study 32552387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/tablet) + anti-TB therapy
Number of subjects: 348
Study 32552387 — intervention group
Group type: COMPARATOR
Intervention: Placebo + anti-TB therapy
Number of subjects: 348
Study 35358648 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, patient-centered rehabilitation program
Number of subjects: 74
Study 35358648 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial within cohort (TWIC) design
Number of subjects: 74
Study 35358648 — intervention group
Group type: EXPERIMENTAL
Intervention: TWIC design
Number of subjects: 74
Study 33621479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond tissue adhesive
Number of subjects: 38
Study 33621479 — intervention group
Group type: COMPARATOR
Intervention: 5/0 Prolene sutures
Number of subjects: 38
Study 35988120 — intervention group
Group type: EXPERIMENTAL
Intervention: +EFT
Number of subjects: 104
Study 35988120 — intervention group
Group type: COMPARATOR
Intervention: +SR
Number of subjects: 104
Study 32940699 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light treatment arm
Number of subjects: 36
Study 32940699 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA treatment arm
Number of subjects: 36
Study 32974656 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (ACT) for adolescents
Number of subjects: 28
Study 32974656 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (ACT) for parents
Number of subjects: 28
Study 32974656 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered ACT for adolescents
Number of subjects: 28
Study 35063241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet with gluten (5 gr/day of gluten powder)
Number of subjects: 49
Study 35063241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 gr of rice flour) with low FODMAP diet
Number of subjects: 49
Study 33130107 — intervention group
Group type: EXPERIMENTAL
Intervention: One Key Question (OKQ) intervention in primary care
Number of subjects: 170
Study 33130107 — intervention group
Group type: EXPERIMENTAL
Intervention: One Key Question (OKQ) intervention in ob/gyn
Number of subjects: 170